Happy Thursday.

In today’s issue:

Angel funding rounds announced in recent weeks, compiled from public sources or via direct announcement. These deals represent the elite few that survived an angel network’s vetting process. Note: I have not personally analyzed these companies and am sharing for informational purposes only.

📊 Angel Network Investment Tracker: 230 Deals, 117 Networks.

🔓 The Exclusive: 11 Actively Raising Deals Shared to Date (1 Added Last Week)

Participating Group: OMA Business Angels

Valuemize is developing a product lifecycle costing platform that sits between enterprise resource planning (ERP) and product lifecycle management (PLM) systems, R&D, finance and procurement teams simulate the cost impact of decisions in real time. The company says its automation tools cut non-value-adding work by more than 50% and reduce product costs by up to 20%. Valuemize recently closed a seven-figure pre-seed round backed by OMA Business Angels alongside xdeck, superangels, Prequel Ventures and PRXS Technology and Investment.

Michael Domanegg | Zurich, Switzerland | July 2026 | Source

Participating Groups: Plains Angels, Ankeny Angels, and FIN Capital Investor Association

Genvax Technologies is developing next-generation mRNA (messenger RNA) and nanoparticle vaccines for livestock animal health. Co-founders Joel Harris and Dr. Hank Harris previously built Harrisvaccines, sold to Merck Animal Health in 2015. Genvax recently joined the portfolios of Plains Angels, Ankeny Angels, and FIN Capital Investor Association.

Joel Harris | Ames, IA | July 2026 | Source

Participating Group: Bridge Angel Investors

DefEYE, Inc. is developing decellularized biologic membranes, grafts made from placental tissue with donor cells removed, to treat ocular surface disease and support eye surgery recovery. Its BIOVANCE 3L Ocular product uses a triple layer design that the company says allows room temperature storage. Bridge Angel Investors recently announced an investment in the Sarasota-based company, citing its focus on specialized eye care in the Sarasota-Manatee region. Funds will support DefEYE's continued commercialization of its ophthalmic biologics portfolio.

Rob Sambursky | Sarasota, FL | July 2026 | Source

Every week, I feature a subset of these deals using public information, which rarely says whether the round is still open. I don’t know until I ask. So I ask. When one is still raising, the deal goes into a private portal with the deck, a memo, terms, and how to reach the founder. I’ve shared 11 deals in the 6 weeks since launch.

Claim one of just 25 founding seats: $50/month for as long as you stay, full refund within 30 days if you’re not finding it useful. Accredited investors only.

In any low margin, high volume business, one word matters above all else: e c o n o m i c s. And that certainly seems to apply in FoodTech - Peter said he repeated this warning to founders constantly: “If what you're doing is 10x better, but it costs a nickel a unit more, you're sunk.” Exhibit A: cultivated meat.

In theory, the concept makes a lot of sense - the tech is there after years in development in the pharma world. But a customer’s willingness-to-pay for a cancer drug and willingness-to-pay for a steak are two wildly different things, so “dropping in” the technology requires a vastly different strategy.

Takeaway: In FoodTech investments, underwrite the unit economics BEFORE the innovation story. A brilliant product with a broken cost structure will not work commercially.

Want more? Check out my full conversation with Peter 👇

Listen now on Apple Podcasts, Spotify, YouTube, and more.

You don't have to scroll every AI thread, track every new tool, or watch every demo. 

The Rundown AI breaks it all down for you — the latest AI news, tools, and tutorials in one free 5-minute email every morning. 

Trusted by 2M+ professionals at Apple, Google, and NASA.

Sign up to start learning.

Thanks for reading - have a great week.

-Andrew

If you’re finding this newsletter valuable, share it with a friend, and consider subscribing if you haven’t already. You can also find me on LinkedIn and X.

Advertise with The Diligent Observer.